Emergent BioSolutions Secures $41.9 Million BARDA Option for Ebanga™ Ebola Treatment Development

GAITHERSBURG, Md., Sept. 12, 2024 – Emergent BioSolutions Inc. EBS, a global life sciences company, has received a substantial financial boost with a $41.9 million option granted by the Biomedical Advanced Research and Development Authority (BARDA). This option, which is a modification to an existing contract, paves the way for the continued advancement and procurement of Ebanga™, the company's therapeutic treatment designed specifically to combat Ebola.

Advancing Ebola Treatment Options

The funding from BARDA signifies a strong commitment to public health and the fight against Ebola, a virus that periodically resurfaces causing severe outbreaks. Ebanga™, an antiviral treatment, has the potential to substantially improve the survival rates of those infected with the virus. The dedication of additional resources for development, reflects the government's proactive stance on controlling future outbreaks and ensuring preparedness.

Impact on Emergent BioSolutions

For EBS, this contract modification is a testament to the company's expertise and reliability in producing therapies for infectious diseases – areas of significant interest to both government agencies and public health entities. The funding will aid in optimizing the production, distribution, and availability of Ebanga™, ultimately aligning with the company's mission to protect and enhance life. This strategic investment not only supports EBS's ongoing projects but potentially strengthens its position in the biopharmaceutical market.

Emergent, BARDA, Ebola